Target Price | $48.96 |
Price | $26.54 |
Potential |
84.48%
register free of charge
|
Number of Estimates | 13 |
13 Analysts have issued a price target Harmony Biosciences Holdings 2026 .
The average Harmony Biosciences Holdings target price is $48.96.
This is
84.48%
register free of charge
$65.10
145.29%
register free of charge
$31.31
17.97%
register free of charge
|
|
A rating was issued by 17 analysts: 14 Analysts recommend Harmony Biosciences Holdings to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Harmony Biosciences Holdings stock has an average upside potential 2026 of
84.48%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 714.73 | 858.29 |
22.80% | 20.09% | |
EBITDA Margin | 30.04% | 32.44% |
19.02% | 8.01% | |
Net Margin | 20.36% | 21.41% |
8.05% | 5.18% |
13 Analysts have issued a sales forecast Harmony Biosciences Holdings 2025 . The average Harmony Biosciences Holdings sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Harmony Biosciences Holdings EBITDA forecast 2025. The average Harmony Biosciences Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Harmony Biosciences Holdings Analysts have issued a net profit forecast 2025. The average Harmony Biosciences Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.51 | 3.19 |
17.84% | 27.09% | |
P/E | 8.31 | |
EV/Sales | 1.32 |
13 Analysts have issued a Harmony Biosciences Holdings forecast for earnings per share. The average Harmony Biosciences Holdings EPS is
This results in the following potential growth metrics and future valuations:
Harmony Biosciences Holdings...
Analyst | Rating | Action | Date |
---|---|---|---|
Deutsche Bank |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Needham |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Deutsche Bank |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | May 15 2025 |
Analyst Rating | Date |
---|---|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Needham:
Locked
➜
Locked
|
Sep 24 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Deutsche Bank:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
May 15 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.